GOLDEN, Colo.–(BUSINESS WIRE)–Feb 9, 2021–
PharmaJet®, the maker of innovative, needle-free injection technology, today announced that Marian Wentworth has been appointed to its Board of Directors. Ms. Wentworth, President and CEO of Management Sciences for Health, is an accomplished global health executive with extensive experience in global strategy, innovation, and development.
Ron Lowy, Executive Chairman, PharmaJet Inc. said, “We are very pleased to welcome Ms. Wentworth to the PharmaJet Board of Directors. Her global health experience with NGO’s and senior management experience at Merck, combined with her strategic vision and operations expertise will be a valuable addition to our board.”
Since 2017, Ms. Wentworth has been President and CEO of Management Sciences for Health, a nonprofit organization that works with low- and middle-income markets across 30 countries to strengthen their health systems. In that role she manages a team of 1200 professionals working on a national, district and local level to deliver health products and services from business management to pharmacy, labs, and clinical care. Previously, Ms. Wentworth held executive roles at Merck & Co., most recently as Vice President, Global Vaccines Strategy and Innovation, where she was responsible for the $6 billion global vaccines business. During her tenure at Merck, she also held executive commercial strategy and operations roles for several vaccines including Varicella, Zostavax, Afluria, and Gardasil to name a few. Ms. Wentworth is Chair of the Board of Medsource, a privately held group purchasing organization in Kenya. She holds a Bachelor of Arts degree in Mathematics from Harvard University.
Ms. Wentworth added, “I look forward to joining PharmaJet’s Board of Directors during this critical time for vaccine development and execution, and using my broad vaccine operational and development expertise to accelerate the adoption of PharmaJet’s needle-free solution.”
For more information about PharmaJet visit www.pharmajet.com.
About PharmaJet
PharmaJet’s mission is worldwide acceptance of PharmaJet Needle-free Injection Systems as a standard of care in the vaccine delivery market. The PharmaJet Needle-free Systems are safe, fast, and easy-to-use. They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210209005005/en/
CONTACT: Nancy Lillie
[email protected]
1-888-900-4321 Option 3
KEYWORD: COLORADO UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: INFECTIOUS DISEASES PHARMACEUTICAL HEALTH MEDICAL DEVICES
SOURCE: PharmaJet
Copyright Business Wire 2021.
PUB: 02/09/2021 08:08 AM/DISC: 02/09/2021 08:08 AM
http://www.businesswire.com/news/home/20210209005005/en
